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Summary 
19 
In horses, cutaneous mast cell tumours (CMCT) are generally considered as benign skin 20 
lesions, although recurrent and multicentric tumours have been described. In canine CMCT, 21 
grading and prognostic approaches are well established and aberrant KIT expression as well 22 
as high proliferation indices are associated with poor outcome. For equine CMCT, however, 23 
morphological features, proliferative activity and KIT expression pattern have so far not been 24 
assessed and considered in relation to their clinical behaviour, and there is ongoing discussion 25 
as to whether CMCT are true neoplastic processes. The aim of the present study was to 26 
morphologically characterise equine CMCT and assess their KIT expression and proliferative 27 
activity, as tools to identify features that would confirm their neoplastic origin and suggest a 28 
variable clinical behaviour. For this purpose, 45 equine CMCT were re-examined to 29 
characterise their morphology as well as KIT and PCNA expression, using light microscopy 30 
including immunohistochemistry. The KIT expression pattern was classified as membranous 31 
(I), cytoplasmic and focally stippled (II), or diffuse cytoplasmic (III). A large proportion of 32 
tumours presented as multinodular or diffuse dermal infiltrates of mast cells with mild 33 
anisokaryosis, a low proliferative rate, and a dominance of KIT pattern I, representing well 34 
differentiated (WD-)CMCT. In approximately one third of the cases, however, the mast cells 35 
exhibited a more infiltrative growth pattern, moderate to marked anisokaryosis and a higher 36 
degree of proliferation. These were classified as poorly differentiated (PD-)CMCT and also 37 
exhibited KIT pattern II and III exclusively. The results of the present study indicate that a 38 
subgroup of poorly differentiated CMCT exist, with evidence of an association between 39 
aberrant KIT expression, high proliferative rate and a potential aggressive behaviour, all 40 
features that confirm at least the PD-CMCT as true neoplastic processes. 41 
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44 
Introduction 
45 
Cutaneous mast cell tumours (CMCT) are relatively uncommon in horses (3.4% of 
46 
cutaneous neoplasms in a recent survey (Valentine et al., 2006)) however, due to the limited 
47 
number of publications on equine CMCT, their prevalence might be underestimated. CMCT 
48 
generally occur in young to adult horses, and predominantly as solitary dermal lesions (Scott 
49 
& Miller, 2011). They are grossly similar to their canine counterparts and occur as nodular 
50 
masses with a diameter of up to 20 cm, most frequently on the head, but often also on the 
51 
trunk and limbs. The overlying skin is intact, alopecic or ulcerated (Kay et al., 2003; Scott &. 
52 
Miller, 2011).   
53 
Histologically, equine CMCT are composed of large single or multiple aggregates of 
54 
mast cells, intermingled with variable numbers of eosinophils and, occasionally, multifocal 
55 
areas of collagenolysis (Scott & Miller, 2011). All these features are also observed in other 
56 
equine skin lesions, among which “equine eosinophilic granuloma” (EEG), a specific chronic 
57 
inflammatory condition characterised by focal infiltrations of macrophages intermingled with 
58 
abundant eosinophils and occasionally mast cells (Scott & Miller., 2011), is the most 
59 
prevalent. However, CMCT are, as the name implies, the only condition that is considered as 
60 
a neoplastic process, although there are ongoing discussions whether some might represent a 
61 
reactive process.  
62 
Equine CMCT are generally considered as clinically benign, although recurrent and 
63 
multicentric tumours have occasionally been described (Riley et al., 1991; Tan et al., 2007). 
64 
In contrast, a recurrence and metastasis rate of approximately 10% and 23% respectively has 
65 
been reported for the canine counterpart (Kiupel et al., 2011). Attempts to relate prognosis 
66 
and morphological features grouped canine CMCT in 3 (grades I to III) or, later, 2 (“high” or 
67 
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“low” grade) categories said to predict the clinical outcome in the affected dog (Kiupel et al., 
68 
2011; Patnaik et al., 1984).  
69 
Development, survival and proliferation of mast cells is regulated by the stem cell 
70 
factor (SCF), a haemopoietic cytokine that acts as a membrane ligand and interacts with the 
71 
c-kit gene product KIT, a tyrosine kinase receptor also known as CD117 (Wedemeyer et al., 
72 
2000). C-kit is a proto-oncogene that is expressed in mast cells and several other cells, such 
73 
as basophils, haematopoietic stem cells, melanocytes and Cajal’s cells in the lamina 
74 
muscularis of the digestive tract (Hudson et al., 2001). In canine CMCT, a tandem 
75 
duplication mutation in the juxtamembrane c-kit coding region has been shown to cause 
76 
activation of the KIT receptor in the absence of SCF (Webster et al., 2004). Studies suggest 
77 
that this gene may have a substantial role in the neoplastic transformation of mast cells in 
78 
dogs and have highlighted its usefulness as a prognostic and predictive marker (Webster et 
79 
al., 2004; Yamada et al., 2011). Immunohistochemical studies have shown KIT expression in 
80 
both normal and neoplastic canine mast cells, but with different staining patterns and 
81 
intensity depending on the MCT grades (Reguera et al., 2000); in the Patnaik grading system, 
82 
grade I tumours exhibit the lowest and grade III the highest staining intensity (Reguera et al., 
83 
2000). Also, in well differentiated neoplastic mast cells, KIT expression was found on the 
84 
cell membrane, whereas the neoplastic cells in high grade tumours exhibited a predominantly 
85 
intracytoplasmic reaction (Reguera et al., 2000). Indeed, translocation of KIT from the 
86 
plasma membrane to the cytoplasm was shown to be associated with tumour recurrence and 
87 
shorter overall survival in the dog (Webster et al., 2004).  
88 
So far, studies on the expression of KIT in equine CMCT are very limited. Abnormal 
89 
cytoplasmic KIT expression in neoplastic cells has been reported in a MCT on the tongue of a 
90 
mare, without evidence of tumour recurrence or metastatic disease within 8 months after 
91 
surgery (Seeliger et al., 2007). Also, a recent study did not find any correlation between KIT 
92 
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expression and morphological parameters of malignancy, clinical outcome, or aggressive 
93 
local behaviour; this was interpreted as evidence of the generally benign behaviour and high 
94 
degree of differentiation of equine CMCT (Clarke et al., 2014).  However, in contrast to this 
95 
recent publication, in our diagnostic case material, we observed a proportion of equine 
96 
CMCT with morphological criteria of malignancy. Therefore, we retrospectively examined a 
97 
cohort of randomly chosen equine CMCT for morphological parameters of malignancy, 
98 
proliferation indices, and KIT expression. 
99 
 
100 
Materials and methods 
101 
Tissues and histological examination  
102 
A total of 45 surgically excised and routinely diagnosed equine CMCT (all with >50% mast 
103 
cells in the infiltrate) were retrieved from the diagnostic database of the Division of 
104 
Veterinary Pathology, School of Veterinary Science, University of Liverpool (2004-2012) 
105 
and the diagnosis confirmed by systematic re-examination. For the assessment of 
106 
morphological criteria, consecutive sections (4 µm) were prepared from each tumour and 
107 
stained with haematoxylin and eosin (HE) and toluidine blue (TB) or used for 
108 
immunohistochemistry (IHC).  
109 
A range of morphological parameters were assessed on the HE and TB stained sections and 
110 
scored as follows: completeness of excision (0 = complete; 1 = incomplete), local growth 
111 
pattern (1 = nodular; 2 = multinodular; 3 = multinodular to infiltrative; 4 = infiltrative), 
112 
vascular invasion (0 = absent; 1 = present), as well as neoplastic mast cell granularity (1 = 
113 
mild; 2 = mild to moderate; 3 = moderate; 4 = moderate to marked; 5 = marked), 
114 
anisokaryosis (1 = mild; 2 = moderate; 3 = marked), nuclear pleomorphism (0 = absent; 1 = 
115 
present), and presence of binucleated neoplastic cells (0 = absent; 1 = present). The mitotic 
116 
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index (MI) was established as the number of mitotic figures per 10 randomly chosen 
117 
representative high power fields (HPF; 400x).  
118 
Immunohistochemistry (IHC) 119 
IHC served to assess the KIT and PCNA expression in neoplastic mast cells. Briefly, 120 
after deparaffinisation and rehydration, sections were incubated in EDTA pH 9.0 in a 121 
microwave oven (4 min at 350 watts, followed by 15 min at 650 watts) for antigen retrieval. 122 
Endogenous peroxidases were blocked with Dako Real Peroxidase-Blocking Solution (Dako, 123 
Glostrup, Denmark). Sections were then incubated for 15-18 h at room temperature with 124 
rabbit anti human-KIT (Dako, Gostrup, Denmark; 1:500 in Tris buffered saline and Tween 125 
0.05% (TBST)) or mouse anti-PCNA (clone PC10, Dako; 1:100 in TBST), known to cross-126 
react with equine KIT (Clarke et al., 2014) and PCNA (Maja et al., 2013) respectively. After 127 
incubation with an anti-rabbit or anti-mouse polymer based detection system (Envision Plus, 128 
Dako), the peroxidase reaction was developed with diaminobenzidine (Impact DAB, Vector 129 
Labs Inc., Burlingame, USA), followed by counterstaining with Papanicolaou’s 130 
haematoxylin. Consecutive sections incubated with non-immune rabbit serum or a murine 131 
subclass matched unrelated primary monoclonal antibody served as negative controls. 132 
Sections of a normal equine dermis with a few non-neoplastic mast cells and sections from an 133 
unaltered jejunum (containing Cajal’s cells) served as positive controls for KIT, while 134 
sections of lymph node and epidermis were used as positive PCNA controls.  135 
The KIT expression pattern was determined according to parameters published for 136 
canine CMCT (Webster et al., 2004). To specify: With KIT staining pattern I, the majority of 137 
neoplastic cells exhibited a membrane reaction, occasionally together with faint cytoplasmic 138 
staining; staining pattern II was represented by an intense, focally clustered cytoplasmic KIT 139 
reaction or a strong stippling throughout the cytoplasm, and staining pattern III by diffuse 140 
cytoplasmic granular staining in mast cells that obscured all other cytoplasmic features. 141 
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Tumours in which more than one pattern was seen (mixed pattern) were classified according 142 
to the predominant pattern.   143 
PCNA expression was seen predominantly in the nucleus (non-mitotic proliferating 144 
cells) or, more rarely, the cytoplasm (cells undergoing mitosis), and the average number of 145 
PCNA-positive cells per 10 randomly chosen representative HPF was used as the PCNA 146 
index.  147 
 148 
Follow-up study and statistical examinations 149 
A retrospective follow up survey form was sent to the veterinary surgeons who had 150 
submitted the diagnostic specimens. The form included questions regarding the recurrence of 151 
the neoplasm after surgical excision, the disease-free survival time, and the overall survival 152 
of the patient. An attempt was made to correlate the follow up data with the histological data 153 
(i.e. KIT staining patterns, morphological features, proliferation indices). 154 
The statistical association between morphological parameters, proliferation indices 155 
and KIT staining patterns was investigated with the Chi-square (for category variables) or 156 
Mann-Whitney (for numerical variables) statistical tests, using the SPSS 13 Software (SPSS 157 
13.0, SPSS Inc, IBM Chicago, USA). Correlation between MI and PCNA score was 158 
determined using Pearson’s Rho (R). Statistical significance was based on a 5% (0.05) level.   159 
 160 
Results 161 
Tumours mainly originated from the head (22/45; 48.8%), some from the legs (6/45; 13.4%) 
162 
and trunk (3; 6.7%); in 14 cases (31.1%), information on the location was not available. The 
163 
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age of affected animals at the time of CMCT diagnosis ranged from 3 to 13 years (average: 
164 
12 years). The majority of affected horses were geldings (25/45; 55.6%), among the 
165 
remaining patients were 3 (6.7%) stallions and 12 (26.7%) mares, in the remaining 5 cases 
166 
(11%), information on the gender was not provided. Arabian (10) with Arabian cross (1) 
167 
(11/45; 24.4%) and Thoroughbred (5) with Thoroughbred cross (6) (11/45; 24.4%) horses 
168 
were most frequently affected. Other affected breeds included Warmblood (3), French breed 
169 
(2), Irish (2), Connemara (1), Irish Sports Pony (1), Appaloosa (1), Native bred (1), Standard 
170 
bred (1), and Coloured Cob (1); in 10 cases (22.2%), the breed was not known.  
171 
The histological examination of the surgically excised tissue showed that the vast 
172 
majority (41/45; 91.1%) of the infiltrates were incompletely excised, in only 8.9 (4/45) did 
173 
they not extend to the surgical margins. Neoplasms varied in size (2-15 cm diameter) and 
174 
were characterised by a predominantly multinodular or more diffuse and locally infiltrative 
175 
growth of mast cells with variable numbers of infiltrating eosinophils. There was no evidence 
176 
of blood or lymphatic vessel infiltration. The cytoplasmic granularity of the mast cells varied 
177 
and did not exhibit a dominant pattern, as identified on the TB-stained sections. Binucleated 
178 
cells were only detected in one case, where they were seen in small numbers.  In two thirds 
179 
(30/45) of the cases, the mast cells exhibited small (7-10 µm in diameter) hyperchromatic 
180 
nuclei with compact chromatin and inconspicuous nucleoli. They generally showed only mild 
181 
anisokaryosis (score 1) and no nuclear pleomorphism (score 0). Based on these criteria, these 
182 
CMCT were grouped as “well differentiated cutaneous mast cell tumours” (WD-CMCT, Fig. 
183 
1A). In contrast, in the remaining one third (15/45) of tumours, the mast cells exhibited  
184 
nuclear pleomorphism (score 1) and moderate or marked anisokaryosis (scores 2 or 3). These 
185 
were grouped together as “poorly differentiated cutaneous mast cell tumours” (PD-CMCT, 
186 
Fig. 1B; Table 1). Furthermore, local infiltrative growth was significantly associated with 
187 
PD-CMCT (Table 2). 
188 
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The degree of mast cell proliferation was assessed based on the mitotic index (MI) 189 
and the amount of PCNA positive cells. MI and PCNA scores showed a significant positive 190 
correlation (R: 0.829, P<0.01). Within the entire study population, the median of the MI and 191 
PCNA score was 0 (range: 0-12) and 11 (range: 0-150), respectively; in 60% of the cases 192 
(27/45), mitotic figures were not observed at all. In WD-CMCT, the PCNA score median was 193 
2 (range: 0 to 50; Fig. 1C) and the MI median was 0 (range: 0-6), whereas in PD-CMCT, it 194 
was 49.5 (range 1 to 150; Fig. 1D) and 3.5 (range: 0-12), respectively (Table 2), confirming a 195 
significant difference (P<0.001) in the proliferative activity of the mast cells in both tumour 196 
groups.   197 
KIT was expressed by both normal mast cells in the positive control sections and the 198 
mast cells in all CMCT. The normal dermal mast cells, like the Cajal’s cells in the jejunum, 199 
consistently exhibited a peripheral membrane reaction. This was also observed in the mast 200 
cells of the majority of CMCT (39/45; 86.7%; KIT pattern I; Fig. 1E). However, in two of the 201 
cases classed as PD-CMCT (4.4% of all cases; 13.3% of the PD-CMCT), a focally stippled 202 
perinuclear cytoplasmic reaction (pattern II) was seen, and in another 4 PD-CMCT (8.9% of 203 
all cases; 26.6% of the PD-CMCT) a diffuse granular cytoplasmic reaction (pattern III; Fig. 204 
1F) was observed. The outcome of the assessment of the KIT staining pattern in relation to 205 
the morphological features is summarised in Table 1, and the significant correlation with poor 206 
mast cell differentiation in Table 2.  KIT patterns II and III were significantly correlated with 207 
a higher anisokaryosis score, both when KIT patterns I and III were compared with each 208 
other (p< 0.05) (Fig. 2A) and when KIT patterns II and III were compared with KIT pattern I 209 
(p<0.01) (Fig. 2B). Similarly, a significant difference in MI or PCNA score was observed 210 
between KIT pattern I and III (Fig. 2C, E) or KIT pattern I and II+III cases (Fig. 2D, F).  211 
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Complete follow-up information was obtained from the referring clinicians in 9/45 212 
cases (20%). Among these were 6 tumours with KIT pattern I (4 WD- and 2 PD-CMCT), of 213 
which 3 (2 PD- and 1 WD-CMCT) had recurred, in one PD-CMCT case within 1 month and 214 
the second within 2 years; for the WD-CMCT, information on the time scale was not 215 
provided. The one PD-CMCT with KIT pattern II (PCNA score: 25, MI: 1) from which 216 
follow-up information was obtained had recurred at the site of surgery within 1 month. Also, 217 
one of the two PD-CMCT with KIT pattern III (PCNA score: 83, MI: 4) with complete 218 
follow-up information had recurred and the horse died 26 month after surgery for unknown 219 
reasons. Eight animals (88.8%) were alive when the study was completed. 220 
 221 
Discussion 222 
The present study investigated the morphological characteristics, proliferative activity 223 
and immunohistochemical KIT expression pattern in equine CMCT. It was performed in an 224 
attempt to gather data on a potential heterogenicity of equine CMCT with regards to 225 
differentiation and clinical behaviour and based on the assessment of features known to 226 
reflect the behaviour of CMCT in other species (Webster et al, 2004; Kiupel et al., 2011). .  227 
The average age of affected horses was 12 years, similar to that recorded in a recent 228 
study (Clarke et al, 2014); however, the generally wide age spread confirms that CMCT can 229 
develop at any age in horses. Like others before, we also found male horses to be more 230 
frequently affected than mares (Scott & Miller, 2011; Clarke et al., 2014). Breed 231 
predilections have only recently been suspected, in a study where Arabians were identified as 232 
being 5.1 times more at risk of developing a CMCT than other equine breeds (Scott & Miller, 233 
2011; Clarke et al., 2014). We observed CMCT most frequently in Arabian (cross) and 234 
Thoroughbred (cross) horses, but without statistical risk association. The head has been 235 
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reported as the predominant site for equine CMCT (Valentine, 2006), and this was also the 236 
site most frequently affected in our case series, followed by the legs and trunk.  237 
Histologically, our CMCT population was in the majority (two thirds) represented by 238 
infiltrates of well differentiated mast cells, predominantly without any morphological 239 
evidence of malignancy. We subsequently addressed these tumours as WD-CMCT. However, 240 
one third of the cases was composed of less differentiated mast cells and exhibited some 241 
morphological features of malignancy, including a tendency for local infiltrative growth; we 242 
classified these as PD-CMCT. The latter differed significantly from the WD-CMCT also in 243 
terms of their proliferative activity. Based on the criteria that we assessed, WD- and PD-244 
CMCT could easily be discerned. Interestingly, a recent study on a larger equine CMCT 245 
cohort conducted in the USA did not find evidence of such a diversity, but reported all 72 246 
tumours in their study to be composed of well differentiated mast cells, with only “minimal” 247 
anisocytosis, anisokaryosis and mitotic figures (Clarke et al., 2014). Several factors may be 248 
responsible for the differences between the results of the two studies. Firstly, Clarke and co-249 
authors applied different inclusion criteria; while a large proportion of lesions (44%) in their 250 
study contained only an “estimated percentage of mast cells in the lesion” of up to 25%, we 251 
have excluded processes in which mast cells represented a minority (<50% of the section 252 
area) to avoid inclusion of potentially non-neoplastic mast cell rich processes (Scott & Miller, 253 
2011). Unfortunately, the lack of photographic documentation of the previous publication 254 
does not allow a direct comparison (Clarke et al., 2014). Secondly, it is possible that different 255 
morphological grading systems were applied. However, since specific information on scores 256 
or measurements used for the qualitative and/or (semi)quantitative assessments is not 257 
provided in the published paper (Clarke et al., 2014), a direct comparison is, again, not 258 
possible. In any case, this recent study reported only 3 cases (4%) with more than 2 mitotic 259 
figures per 10 HPF (Clarke et al., 2014), a cut off MI that would in our study identify 13 260 
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CMCT (29%), the majority of which (10/13) belong to the tumours classified as PD-CMCT. 261 
Thirdly, it cannot be excluded that epidemiological and genetical differences between the two 262 
study populations from the USA and Great Britain, respectively, could account for the 263 
discrepancy between the results of the two studies.  264 
Our immunohistochemical assessment of the KIT expression patterns in neoplastic 265 
cells yielded results that were very similar to those obtained in the previous study, although 266 
we observed a slightly higher frequency of patterns II and III (15% vs. 12%) (Clarke et al., 267 
2014). However, when we evaluated KIT expression and proliferative activity together, we 268 
observed that CMCT with KIT expression patterns II and III all had a high proliferative 269 
activity.  270 
In the aforementioned study the authors conclude that the KIT expression pattern is 271 
not associated with clinical outcome or tumour behaviour and gain their conclusions from 272 
data generated by a retrospective follow-up study that was designed in a similar way to ours. 273 
The authors had obtained relevant follow-up information in 30% of their cases (n=20/72) 274 
(Clarke et al., 2014). Unfortunately, we were only able to gather complete follow-up 275 
information on 20% of our cases. It is our opinion that the numbers of both studies are too 276 
low to be fully representative of the whole study population, since the clinical behaviour of 277 
the majority of cases (70% and 80% respectively) is completely unknown. However, it is 278 
interesting to note that 4 of the 5 CMCT that we found to have recurred were PD-CMCT, and 279 
among these was the only horse that died before the end of the retrospective follow up study. 280 
In our opinion, larger and prospective studies are needed to further comment on the 281 
behaviour and potential associated morphology, proliferative indices and/or KIT expression 282 
pattern as potential prognostic markers for equine CMCT. However, based on our 283 
observations, KIT translocation from the cell membrane to the cytoplasm is a phenomenon 284 
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that is only seen in a subgroup of equine CMCT with a lower degree of mast cell 285 
differentiation, morphological features of malignancy and a higher proliferative activity.  286 
In canine CMCT, c-kit mutation has been reported (Yamada et al., 2011), but 287 
evidence of an association between c-kit mutation and an abnormal c-KIT protein expression 288 
pattern has been inconsistent (Fett et al., 2013; Webster et al., 2004). Our 289 
immunohistochemical results suggest that such mutations may also occur in equine CMCT, 290 
and more frequently than previously anticipated, as there is some evidence of an association 291 
between various mutations in this gene and a white colour coat phenotype in several horse 292 
breeds (Haase et al., 2009). Whether these mutations are also associated with abnormal 293 
immunohistochemical KIT expression in horses, or specifically in CMCT, remains to be 294 
determined, and further studies are needed to investigate this in more detail. 295 
Conclusions 296 
Our study identified a subpopulation of poorly differentiated equine CMCTs with 297 
morphological features of malignancy, a higher proliferative activity and abnormal KIT 298 
expression. Although the clinical follow-up data was too limited to allow a valid assessment 299 
of the relationship between morphological features, proliferation, KIT expression patterns 300 
and prognosis in equine CMCTs, the results provide a rational basis for further research in 301 
this area, confirm that at least a certain proportion of processes that are currently classified as 302 
equine CMCT are true neoplastic processes, and support the hypothesis that a proportion of 303 
CMCTs is at least locally aggressive.    304 
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Figure Legends 372 
 373 
Fig. 1. Morphology , KIT and PCNA expression in equine well differentiated (WD-) and 374 
poorly differentiated (PD-) cutaneous mast cell tumours (CMCT). 375 
A. WD-CMCT).  Densely packed neoplastic cells with scattered eosinophils and  mild 376 
anisokaryosis. B. PD-CMCT. The neoplasm is composed of densely packed round cells that 377 
exhibit moderate to marked anisokaryosis (arrow) and mitotic figures (arrowhead). HE stain. 378 
Inset: The presence of abundant metachromatic granules within the cytoplasm of the 379 
neoplastic cells confirms these as mast cells. Tolouidine blue stain. C. WD-CMCT. PCNA-380 
positive proliferating cells (arrowheads) are rare.  D. PD-CMCT. A large number of PCNA 381 
positive, proliferating cells is seen. E. WD-CMCT with KIT pattern I. Mast cells exhibit 382 
membranous KIT expression. F. PD-CMCT with  KIT pattern III. Mast cells exhibit granular 383 
cytoplasmic KIT expression. C-F: Indirect immunoperoxidase, Papanicolaou’s heamatoxylin 384 
counterstain. Scale bars = 20 µm. 385 
 386 
Fig. 2. Association of KIT expression and the presence of anisokaryosis, the mitotic 387 
index and the PCNA score in equine CMCT.  388 
Box and whisker plots to illustrate the association between median anisokaryosis score (A, 389 
B), mitotic index (C, D) and PCNA score (E, F) with KIT patterns I, II and III (A, C, E) or 390 
KIT patterns I and II + III (B, D, F). Circles represent outlayers. * = P < 0.05. ** = P < 0.01.  391 
 392 
 393 
